TGFB1 and neoplasm: The main difference between pharmacologically TGFβ-inhibited CAF/ECM and β5KO CAF/ECM units is that the latter perpetuate a tumor-suppressive “normalized” CAF/ECM unit phenotype and function, while the former is transient.